KR102574135B1 - 히스톤 데아세틸라제 1 및 2 (hdac1-2)의 선택적인 저해제로서 새로운 헤테로아릴 아미드 유도체 - Google Patents
히스톤 데아세틸라제 1 및 2 (hdac1-2)의 선택적인 저해제로서 새로운 헤테로아릴 아미드 유도체 Download PDFInfo
- Publication number
- KR102574135B1 KR102574135B1 KR1020207003894A KR20207003894A KR102574135B1 KR 102574135 B1 KR102574135 B1 KR 102574135B1 KR 1020207003894 A KR1020207003894 A KR 1020207003894A KR 20207003894 A KR20207003894 A KR 20207003894A KR 102574135 B1 KR102574135 B1 KR 102574135B1
- Authority
- KR
- South Korea
- Prior art keywords
- amino
- pyridin
- disease
- fluorophenyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382447 | 2017-07-10 | ||
| EP17382447.5 | 2017-07-10 | ||
| PCT/ES2018/070491 WO2019012172A1 (es) | 2017-07-10 | 2018-07-09 | Nuevos derivados heteroaryl amida como inhibidores selectivos de histona deacetilasa 1 y 2 (hdac1/2) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200038473A KR20200038473A (ko) | 2020-04-13 |
| KR102574135B1 true KR102574135B1 (ko) | 2023-09-01 |
Family
ID=59315557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207003894A Active KR102574135B1 (ko) | 2017-07-10 | 2018-07-09 | 히스톤 데아세틸라제 1 및 2 (hdac1-2)의 선택적인 저해제로서 새로운 헤테로아릴 아미드 유도체 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11241428B2 (https=) |
| EP (1) | EP3653620B9 (https=) |
| JP (1) | JP7026787B2 (https=) |
| KR (1) | KR102574135B1 (https=) |
| CN (1) | CN111051300B (https=) |
| AU (1) | AU2018300123B2 (https=) |
| CY (1) | CY1125343T1 (https=) |
| DK (1) | DK3653620T3 (https=) |
| EA (1) | EA039144B1 (https=) |
| ES (1) | ES2911040T3 (https=) |
| HR (1) | HRP20220472T1 (https=) |
| HU (1) | HUE058353T2 (https=) |
| LT (1) | LT3653620T (https=) |
| MX (1) | MX393982B (https=) |
| PL (1) | PL3653620T3 (https=) |
| PT (1) | PT3653620T (https=) |
| RS (1) | RS63156B1 (https=) |
| SI (1) | SI3653620T1 (https=) |
| SM (1) | SMT202200165T1 (https=) |
| WO (1) | WO2019012172A1 (https=) |
| ZA (1) | ZA202000727B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7736678B2 (ja) | 2019-10-16 | 2025-09-09 | ケモセントリックス，インコーポレイティド | Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド |
| WO2021117759A1 (ja) * | 2019-12-10 | 2021-06-17 | 塩野義製薬株式会社 | 含窒素芳香族複素環式基を有するヒストン脱アセチル化酵素阻害剤 |
| CN114380751B (zh) * | 2020-03-30 | 2025-03-07 | 上海辉启生物医药科技有限公司 | 二氢化茚胺类衍生物、其制备方法和用途 |
| CA3240229A1 (en) | 2021-12-03 | 2023-06-08 | Tango Therapeutics, Inc. | Novel hdac inhibitors and therapeutic use thereof |
| CN114524799B (zh) * | 2022-03-11 | 2023-05-26 | 沈阳药科大学 | 一种hdac抑制剂及其制备方法和用途 |
| EP4306106A1 (en) * | 2022-07-14 | 2024-01-17 | Universidade de Aveiro | Nitro-containing compounds, compositions and uses thereof |
| CN115463215A (zh) * | 2022-07-26 | 2022-12-13 | 苏州大学 | Hdac9及其抑制剂的新用途 |
| CA3263654A1 (en) | 2022-08-05 | 2024-02-08 | Tango Therapeutics, Inc. | HISTONE DEACETYLASE INHIBITOR FOR THE TREATMENT OF CANCER WITH ALTERED STK11 ACTIVITY OR EXPRESSION |
| CN115304513A (zh) * | 2022-08-25 | 2022-11-08 | 湖北科技学院 | 具有抗炎活性的查尔酮类衍生物及其合成方法和应用 |
| CN115368277B (zh) * | 2022-09-15 | 2024-03-29 | 华侨大学 | 一种含异羟肟酸结构的联苯类化合物及其应用 |
| CN116199636A (zh) * | 2023-02-21 | 2023-06-02 | 杭州医学院 | 靶向肿瘤免疫激酶的2,4-二取代嘧啶衍生物、制备方法及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010531358A (ja) | 2007-06-27 | 2010-09-24 | メルク・シャープ・エンド・ドーム・コーポレイション | ヒストン脱アセチル化酵素阻害剤としてのピリジル及びピリミジニル誘導体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007055942A2 (en) * | 2005-11-03 | 2007-05-18 | Merck & Co., Inc. | Substituted nicotinamide compounds |
| CA2649861A1 (en) * | 2006-04-26 | 2007-11-08 | Merck & Co., Inc. | Disubstituted aniline compounds |
| KR20120031170A (ko) * | 2009-06-08 | 2012-03-30 | 길리애드 사이언시즈, 인코포레이티드 | 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물 |
| US20160137630A1 (en) * | 2014-10-08 | 2016-05-19 | Acetylon Pharmaceuticals, Inc. | Induction of gata2 by hdac1 and hdac2 inhibitors |
| KR20180022840A (ko) * | 2015-07-02 | 2018-03-06 | 바이오마린 파머수티컬 인크. | 히스톤 데아세틸라제 저해제 |
| US9603950B1 (en) | 2015-10-25 | 2017-03-28 | Institute Of Nuclear Energy Research | Compounds of imaging agent with HDAC inhibitor for treatment of Alzheimer syndrome and method of synthesis thereof |
-
2018
- 2018-07-09 ES ES18789777T patent/ES2911040T3/es active Active
- 2018-07-09 SI SI201830644T patent/SI3653620T1/sl unknown
- 2018-07-09 JP JP2020523052A patent/JP7026787B2/ja active Active
- 2018-07-09 AU AU2018300123A patent/AU2018300123B2/en active Active
- 2018-07-09 LT LTEPPCT/ES2018/070491T patent/LT3653620T/lt unknown
- 2018-07-09 PL PL18789777T patent/PL3653620T3/pl unknown
- 2018-07-09 RS RS20220320A patent/RS63156B1/sr unknown
- 2018-07-09 MX MX2020000349A patent/MX393982B/es unknown
- 2018-07-09 DK DK18789777.2T patent/DK3653620T3/da active
- 2018-07-09 US US16/629,457 patent/US11241428B2/en active Active
- 2018-07-09 PT PT187897772T patent/PT3653620T/pt unknown
- 2018-07-09 CN CN201880056722.5A patent/CN111051300B/zh active Active
- 2018-07-09 WO PCT/ES2018/070491 patent/WO2019012172A1/es not_active Ceased
- 2018-07-09 HR HRP20220472TT patent/HRP20220472T1/hr unknown
- 2018-07-09 EP EP18789777.2A patent/EP3653620B9/en active Active
- 2018-07-09 KR KR1020207003894A patent/KR102574135B1/ko active Active
- 2018-07-09 EA EA202090259A patent/EA039144B1/ru unknown
- 2018-07-09 HU HUE18789777A patent/HUE058353T2/hu unknown
- 2018-07-09 SM SM20220165T patent/SMT202200165T1/it unknown
-
2020
- 2020-02-04 ZA ZA2020/00727A patent/ZA202000727B/en unknown
-
2022
- 2022-04-15 CY CY20221100286T patent/CY1125343T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010531358A (ja) | 2007-06-27 | 2010-09-24 | メルク・シャープ・エンド・ドーム・コーポレイション | ヒストン脱アセチル化酵素阻害剤としてのピリジル及びピリミジニル誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3653620B9 (en) | 2022-03-23 |
| JP2020527173A (ja) | 2020-09-03 |
| AU2018300123A1 (en) | 2020-02-13 |
| CY1125343T1 (el) | 2024-12-13 |
| LT3653620T (lt) | 2022-05-10 |
| EP3653620B1 (en) | 2022-02-02 |
| US20200138808A1 (en) | 2020-05-07 |
| ZA202000727B (en) | 2022-07-27 |
| AU2018300123B2 (en) | 2022-03-17 |
| PL3653620T3 (pl) | 2022-06-20 |
| MX2020000349A (es) | 2020-08-17 |
| US11241428B2 (en) | 2022-02-08 |
| CN111051300A (zh) | 2020-04-21 |
| EP3653620A1 (en) | 2020-05-20 |
| WO2019012172A1 (es) | 2019-01-17 |
| ES2911040T3 (es) | 2022-05-17 |
| HRP20220472T1 (hr) | 2022-05-27 |
| HUE058353T2 (hu) | 2022-07-28 |
| SMT202200165T1 (it) | 2022-05-12 |
| DK3653620T3 (da) | 2022-03-28 |
| PT3653620T (pt) | 2022-04-22 |
| KR20200038473A (ko) | 2020-04-13 |
| MX393982B (es) | 2025-03-24 |
| JP7026787B2 (ja) | 2022-02-28 |
| EA202090259A1 (ru) | 2020-05-25 |
| BR112020000564A2 (pt) | 2020-07-21 |
| CN111051300B (zh) | 2022-12-23 |
| CA3069273A1 (en) | 2019-01-17 |
| RS63156B1 (sr) | 2022-05-31 |
| SI3653620T1 (sl) | 2022-05-31 |
| EA039144B1 (ru) | 2021-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102574135B1 (ko) | 히스톤 데아세틸라제 1 및 2 (hdac1-2)의 선택적인 저해제로서 새로운 헤테로아릴 아미드 유도체 | |
| JP6326057B2 (ja) | 置換ピリミジニルおよびピリジニル−ピロロピリジノン、これらの調製のための方法、およびキナーゼ阻害剤としてのこれらの使用 | |
| CA2684037C (en) | Compounds with anti-cancer activity | |
| RU2704129C2 (ru) | Соединение 2-аминопиримидина и фармацевтическая композиция и применение данного соединения | |
| CZ20002349A3 (en) | Inhibition of RAF-kinase by means of aryl- and heteroaryl-substituted heterocyclic ureas | |
| RU2618423C2 (ru) | Усилитель противоопухолевого эффекта, содержащий имидазооксазиновое соединение | |
| WO2014167444A1 (en) | SUBSTITUTED BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | |
| JPWO2012008563A1 (ja) | 含窒素芳香族複素環誘導体 | |
| KR20120016659A (ko) | 단백질 키나제 및 히스톤 디아세틸라제의 억제제로서 나프탈렌 카르복스아미드 유도체, 그 제조 방법 및 용도 | |
| CN105722840B (zh) | 作为PI3K、mTOR抑制剂的稠合喹啉化合物 | |
| JPH04503212A (ja) | ５―リポキシゲナーゼ阻止剤としての４―ヒドロキシチアゾール | |
| SG11202110545TA (en) | Inhibitors of notch signalling pathway and use thereof in treatment of cancers | |
| CN110156782B (zh) | 作为pi3k/mtor抑制剂的吡啶基取代的稠合喹啉化合物 | |
| CA3069273C (en) | Heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and/or 2 (hdac1-2) | |
| JP7815213B2 (ja) | ベンジルアミン誘導体、その調製方法およびその用途 | |
| WO2021129629A1 (zh) | Zeste增强子同源物2抑制剂及其用途 | |
| BR112020000564B1 (pt) | Composto de heteroarilamida como inibidor seletivo das histonas desacetilases 1 e/ou 2 (hdac1-2), composição farmacêutica, uso e combinação do mesmo | |
| SG11202110547YA (en) | Compounds for the treatment of oncovirus induced cancer and methods of use thereof | |
| CN116284043B (zh) | 三环类化合物及其医药用途 | |
| WO2025174889A1 (en) | Malt1 and btk dual inhibitors | |
| KR20230118883A (ko) | Enpp1 억제제로서의 이미다졸 화합물 | |
| US20250353831A1 (en) | Novel heterobicyclic compound for inhibiting yap-tead interaction and pharmaceutical composition comprising same | |
| CN109096178A (zh) | 用于治疗癌症的苯乙炔基取代苯和杂环及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20200210 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210311 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230328 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20230808 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20230830 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20230830 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |